vs
Arcellx, Inc.（ACLX）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是Arcellx, Inc.的119.7倍（$197.9M vs $1.7M）。REPLIGEN CORP净利率更高（6.7% vs -3513.4%，领先3520.1%）。REPLIGEN CORP同比增速更快（13.6% vs -89.2%）。REPLIGEN CORP自由现金流更多（$17.6M vs $-58.9M）。过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -79.5%）
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
ACLX vs RGEN — 直观对比
营收规模更大
RGEN
是对方的119.7倍
$1.7M
营收增速更快
RGEN
高出102.8%
-89.2%
净利率更高
RGEN
高出3520.1%
-3513.4%
自由现金流更多
RGEN
多$76.5M
$-58.9M
两年增速更快
RGEN
近两年复合增速
-79.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7M | $197.9M |
| 净利润 | $-58.1M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | -3850.2% | 9.0% |
| 净利率 | -3513.4% | 6.7% |
| 营收同比 | -89.2% | 13.6% |
| 净利润同比 | -23.4% | 143.9% |
| 每股收益（稀释后） | $-1.01 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLXRGEN
| Q4 25 | $1.7M | $197.9M | ||
| Q3 25 | $4.9M | $188.8M | ||
| Q2 25 | $7.6M | $182.4M | ||
| Q1 25 | $8.1M | $169.2M | ||
| Q4 24 | $15.3M | $174.1M | ||
| Q3 24 | $26.0M | $154.9M | ||
| Q2 24 | $27.4M | $154.1M | ||
| Q1 24 | $39.3M | $151.3M |
净利润ACLXRGEN
| Q4 25 | $-58.1M | $13.3M | ||
| Q3 25 | $-55.8M | $14.9M | ||
| Q2 25 | $-52.8M | $14.9M | ||
| Q1 25 | $-62.3M | $5.8M | ||
| Q4 24 | $-47.1M | $-30.3M | ||
| Q3 24 | $-25.9M | $-654.0K | ||
| Q2 24 | $-27.2M | $3.3M | ||
| Q1 24 | $-7.2M | $2.1M |
毛利率ACLXRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率ACLXRGEN
| Q4 25 | -3850.2% | 9.0% | ||
| Q3 25 | -1248.3% | 8.9% | ||
| Q2 25 | -777.4% | 7.6% | ||
| Q1 25 | -847.6% | 3.9% | ||
| Q4 24 | -348.2% | -17.7% | ||
| Q3 24 | -129.1% | -5.1% | ||
| Q2 24 | -127.8% | 1.0% | ||
| Q1 24 | -40.3% | 1.3% |
净利率ACLXRGEN
| Q4 25 | -3513.4% | 6.7% | ||
| Q3 25 | -1127.1% | 7.9% | ||
| Q2 25 | -698.6% | 8.2% | ||
| Q1 25 | -766.0% | 3.4% | ||
| Q4 24 | -308.4% | -17.4% | ||
| Q3 24 | -99.4% | -0.4% | ||
| Q2 24 | -99.3% | 2.2% | ||
| Q1 24 | -18.3% | 1.4% |
每股收益（稀释后）ACLXRGEN
| Q4 25 | $-1.01 | $0.24 | ||
| Q3 25 | $-0.99 | $0.26 | ||
| Q2 25 | $-0.94 | $0.26 | ||
| Q1 25 | $-1.13 | $0.10 | ||
| Q4 24 | $-0.87 | $-0.55 | ||
| Q3 24 | $-0.48 | $-0.01 | ||
| Q2 24 | $-0.51 | $0.06 | ||
| Q1 24 | $-0.14 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.3M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $402.4M | $2.1B |
| 总资产 | $604.0M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资ACLXRGEN
| Q4 25 | $450.3M | $767.6M | ||
| Q3 25 | $461.4M | $748.7M | ||
| Q2 25 | $453.1M | $708.9M | ||
| Q1 25 | $543.3M | $697.2M | ||
| Q4 24 | $587.4M | $757.4M | ||
| Q3 24 | $574.3M | $784.0M | ||
| Q2 24 | $516.7M | $809.1M | ||
| Q1 24 | $573.9M | $780.6M |
总债务ACLXRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ACLXRGEN
| Q4 25 | $402.4M | $2.1B | ||
| Q3 25 | $440.8M | $2.1B | ||
| Q2 25 | $392.2M | $2.1B | ||
| Q1 25 | $416.9M | $2.0B | ||
| Q4 24 | $454.8M | $2.0B | ||
| Q3 24 | $483.0M | $2.0B | ||
| Q2 24 | $487.2M | $2.0B | ||
| Q1 24 | $496.6M | $2.0B |
总资产ACLXRGEN
| Q4 25 | $604.0M | $2.9B | ||
| Q3 25 | $655.9M | $2.9B | ||
| Q2 25 | $619.1M | $2.9B | ||
| Q1 25 | $648.1M | $2.9B | ||
| Q4 24 | $711.3M | $2.8B | ||
| Q3 24 | $764.9M | $2.8B | ||
| Q2 24 | $734.3M | $2.9B | ||
| Q1 24 | $779.7M | $2.8B |
负债/权益比ACLXRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-58.2M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $-58.9M | $17.6M |
| 自由现金流率自由现金流/营收 | -3563.4% | 8.9% |
| 资本支出强度资本支出/营收 | 46.2% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $-212.6M | $93.9M |
8季度趋势，按日历期对齐
经营现金流ACLXRGEN
| Q4 25 | $-58.2M | $25.7M | ||
| Q3 25 | $-49.2M | $48.1M | ||
| Q2 25 | $-39.7M | $28.6M | ||
| Q1 25 | $-63.1M | $15.0M | ||
| Q4 24 | $-46.0M | $39.2M | ||
| Q3 24 | $30.7M | $49.3M | ||
| Q2 24 | $-36.2M | $42.2M | ||
| Q1 24 | $-31.9M | $44.7M |
自由现金流ACLXRGEN
| Q4 25 | $-58.9M | $17.6M | ||
| Q3 25 | $-49.5M | $43.4M | ||
| Q2 25 | $-40.2M | $21.5M | ||
| Q1 25 | $-63.9M | $11.4M | ||
| Q4 24 | $-47.5M | $33.6M | ||
| Q3 24 | $28.4M | $42.3M | ||
| Q2 24 | $-39.5M | $37.4M | ||
| Q1 24 | $-38.3M | $36.4M |
自由现金流率ACLXRGEN
| Q4 25 | -3563.4% | 8.9% | ||
| Q3 25 | -1000.3% | 23.0% | ||
| Q2 25 | -532.4% | 11.8% | ||
| Q1 25 | -786.4% | 6.8% | ||
| Q4 24 | -311.3% | 19.3% | ||
| Q3 24 | 109.2% | 27.3% | ||
| Q2 24 | -144.1% | 24.3% | ||
| Q1 24 | -97.7% | 24.0% |
资本支出强度ACLXRGEN
| Q4 25 | 46.2% | 4.1% | ||
| Q3 25 | 6.0% | 2.5% | ||
| Q2 25 | 6.4% | 3.9% | ||
| Q1 25 | 9.6% | 2.1% | ||
| Q4 24 | 9.8% | 3.2% | ||
| Q3 24 | 8.8% | 4.5% | ||
| Q2 24 | 11.7% | 3.1% | ||
| Q1 24 | 16.4% | 5.5% |
现金转化率ACLXRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
